Clinically important mutant p53 proteins may be tumorigenic through a dominant-negative mechanism or due to a gain-of-function. Examples for both hypotheses have been described; however, it remains unclear to what extent they apply to TP53 mutations in general. Here it is shown that the mutational spectrum of dominant-negative p53 mutants selected in a novel yeast assay correlates tightly with p53 mutations in cancer. Two classes of dominant-negative mutations are described; the more dominant one affects codons that are essential for the stabilization of the DNAbinding surface of the p53 core domain and for the direct interaction of p53 with its DNA binding sites. These results predict that the vast majority of TP53 mutations leading to cancer do so in a dominant-negative fashion.
More than half of all human cancers are associated with one or more alterations in the tumor suppressor gene TP53 (1) (2) (3) (4) . Many premalignant lesions, a subset of malignant clones and germ lines of families prone to cancer are characterized by the presence of one wild-type and one mutant allele of TP53 (5) (6) (7) (8) (9) . In this situation the mutant p53 protein may act in a dominantnegative fashion, ultimately leading to loss of heterozygosity and thus a further growth advantage for the malignant cells. Alternatively, the mutant p53 protein may have acquired a new tumor-promoting activity which is independent of wild-type p53. These hypotheses are based on the analysis of only a few TP53 mutations, usually in the setting of overexpression of the mutant protein, and their relevance to TP53 mutations in general has not been proven (8, (10) (11) (12) (13) . We decided to use a novel yeast assay for p53 and its consensus DNA binding site to screen for and analyse spontaneous dominant-negative p53 mutations. We show that such mutations cluster in the mutational hot spots of human cancers. We demonstrate different degrees of dominance, the most dominant mutations localizing to codons 179, 241-248, and 277-281. These results are fully consistent with a dominant-negative mode of action for the large majority of tumorigenic TP53 alleles.
MATERIALS AND METHODS
Yeast Strains, Plasmids, and Isolation of p53 Mutants. All of the yeast media used here (e.g., ϪHis) were dropout media based on synthetic complete medium (SC) (14) lacking the indicated nutrient(s). The yeast strains and plasmids used are described in Table 1 .
For isolation of independent p53 mutations, patches of single colonies from RBy41 [containing an ADH-p53 HIS3 expression vector (pRB16) and the integrated reporter gene 1cUAS53ϻURA3; M.V., R.K.B., A. Fattaey, E. Harlow, and J.D.B., unpublished data] were grown on SC ϪHis plates, replica-plated to SC ϪHis ϩ0.15% 5-fluoroorotic acid (Foa) plates, and incubated for 2-4 days at 37°C until Foa R papillae emerged. Only a single Foa R colony was isolated from each parental patch. These Foa R clones were (i) mated to RBy159 (MAT␣, isogenic to RBy41, but lacking an ADH-p53 expression vector) and replica-plated to SC ϪUra plates and (ii) mated to RBy160 [RBy159 with the ADH-p53 LEU2 plasmid pLS76 (15)] followed by replica-plating to SC ϪHis ϪLeu plates to select for diploids and then SC ϪHis ϪLeu ϩ0.15% Foa plates to evaluate the dominance͞recessivity of the Foa R phenotype. Clones which were Ura ϩ in mating assay i and Foa S in assay ii were recessive and were not due to p53 plasmiddependent mutations. Most of these clones represent recessive mutations that knock out 1cUAS53ϻURA3. Clones which were Ura Ϫ in assay i and Foa S in assay ii were p53 plasmid-dependent recessive mutations. Only clones which were Foa R in assay ii potentially contained a dominant-negative p53 plasmiddependent mutation; these were further characterized by growing them nonselectively and isolating strains which had lost the (potentially mutated) pRB16. A wild-type p53 expression plasmid was then introduced into these strains as follows. The plasmidfree strains were mated to RBy162 (MAT␣ ura3-52 and containing pLS76), replica-plated to SC ϪAde ϪLeu plates to select for diploids, followed by replica-plating of the diploids to SC ϪLeu ϩ0.15% Foa plates. Foa R clones which regained their Foa S phenotype as a result of these manipulations were judged to contain dominant-negative p53 plasmid-dependent mutations.
Characterization of p53 Mutants. The mutant pRB16 plasmids from all identified dominant-negative p53 plasmid dependent clones were recovered in bacteria (17) and retransformed into RBy33 (RBy41 without pRB16), and the phenotypes were rechecked. The dominant-negative phenotypes were then further classified by testing the degree of dominance over one or two doses of wild-type ADH-p53 as follows. The retransformed strains bearing mutant pRB16 derivatives were mated to RBy160 and RBy161 [RBy159 containing two ADHp53 expression plasmids, pLS76 (15) and pRB17, which is identical to pRB16 except for the selectable marker TRP1
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Abbreviations: Foa, 5-fluoroorotic acid; SC, synthetic complete medium. § To whom reprint requests should be addressed. 
*All strains listed (except RBy162) are also lys2⌬202 trp1⌬63 his3⌬200 leu2⌬1. RBy162 is also lys2⌬202 trp1⌬63 his3⌬200 leu2⌬1 ade2⌬. † pRB16 and pRB17 were derived from pLS76 (15) by subcloning the Xho I-Sac I fragment containing ADH-p53 (including the CYC1 transcription terminator) into CEN vectors pRS413 and pRS414 (16) , respectively.
(16)]; replica-plating them to SC ϪHis ϪLeu and SC ϪHis ϪLeu ϪTrp plates, respectively; replica-plating them to the same selective plates with 0.15% Foa, and incubating them at 30°C for 2-4 days.
Some of the dominant-negative p53 mutants were isolated as false positives from a cDNA library screen that is irrelevant to this paper; these mutants were characterized in the same fashion ( Table 2 ). Due to the fact that this subset of the mutants studied did not necessarily represent independent isolates, a numerical analysis of mutation frequencies within this subset would be meaningless.
The recessive plasmid-dependent p53 mutants were also recovered into bacteria and retransformed. These isolates (as well as the dominant isolates) were evaluated by immunoblotting with anti-p53 antibody PAb 1801, performed as described (M.V., R.K.B., A. Fattaey, E. Harlow, and J.D.B., unpublished data). RBy50 [pRS413 (16) in RBy33] was used as the negative control.
Sequencing of the Dominant-Negative p53 Mutants. Miniprep DNA (17) for the plasmids was RNase A treated (7 g͞ml for 10 min at 37°C), extracted with phenol͞chloroform and sequenced with Taq polymerase (Perkin-Elmer) using Prizm kit dye-terminator cycle sequencing on an Applied Biosystems model 373A stretch automated sequencer. Sequences were analyzed using SEQUENCHER software (Gene Codes, Ann Arbor, MI) for the Macintosh. The core domains of ADH-p53 were sequenced using primers JB990 (5Ј-ACCAGCAGCTC-CTACACC-3Ј) and JB991 (5Ј-GAGGAGCTGGTGTT-GTTG-3Ј). Eight dominant-negative clones (boldface numbers in Table 3 ) were further analyzed by ligating Nco I͞Stu I fragments with the mutations (base pairs 477-1039) into pRB16 using standard methods (18) . Wild-type sequence for the C-terminal parts of these fragments was verified by sequencing with primers JB1052 (5Ј-CCATCCTCACCATCAT-CAC-3Ј) and JB1091 (5Ј-GCAGGGGAGGGAGAGATGG-3Ј). The hotspot mutations for codons 175 and 249 ( ¶ symbol in Table 3 ) were cloned into pRB16 using the same strategy (M.V., R.K.B., A. Fattaey, E. Harlow, and J.D.B., unpublished data). Phenotypes were checked as described above.
RESULTS
The Assay for p53 and Its Consensus DNA Binding Site. Our p53 assay is based on the principles of yeast systems designed FIG. 1. Phenotypes of p53 mutants selected in yeast. In contrast to wild-type p53 (phenotype Ura ϩ Foa S ), all dominant-negative as well as recessive mutants are Ura Ϫ Foa R . Upon mating to strains with one or two wild-type ADH-p53 expression vectors the dominant-negative mutants can be classified by their degree of dominance over wild-type p53. The stronger class 1 interferes with one and two copies of wild-type ADH-p53 and thus survives on Foa plates. The weaker class 2 is only dominant over one wild-type copy. For the p53 mutants in boldface letters, Nco I͞Stu I fragments with the mutations were recloned into the wild-type ADH-p53 plasmid pRB16. The mutants with ‫ءء‬ represent hot spot codons which were not identified by our screen (1, 2, 4) (see Table 3 ). Mutations #2022 and #2026 are recessive mutations leading to the expression of truncated p53 proteins. The media used were SC ϪUra (ϪU), SC ϪHis ϩFoa (ϪHϩF), SC ϪHis ϪLeu ϩFoa (ϪHϪLϩF), and SC ϪHis ϪLeu ϪTrp ϩFoa (ϪHϪLϪTϩF). The ϪU and ϪHϩF media test for p53 function (wild type grows on ϪU and fails to grow on ϪHϩF). The ϪHϪLϩF medium tests for the ability of mutant p53 to interfere with the function of a single wild-type copy of p53 (present on a LEU2 plasmid); dominant-negative mutants will grow on this medium. The ϪHϪLϪTϩF medium tests for the ability of mutant p53 to interfere with the function of two wild-type copies of p53 (present on LEU2 and TRP1 plasmids). *Thirteen plasmid-dependent mutants could not be classified because they did not show consistent phenotypes before and after plasmid recovery and retransformation. † Eighteen additional independent dominant-negative mutants were obtained as false positives in a cDNA library screen. These mutants are independent by virtue of a unique mutation and are identified by ‫ء‬ in Table 3 . (1996) p53 mutants that behaved in a dominant-negative fashion. These mutants were identified using a two-step selection procedure. In the first step, haploid yeast colonies deficient in URA3 expression were selected on plates containing Foa. In the second step, these colonies were mated to strains containing either the wild-type reporter gene or one copy of wild-type ADH-p53 and subsequently transferred to plates containing Foa. Dominant-negative alleles of p53 showed an Foa R phenotype in both cases. Recessive alleles of p53 or cis-acting reporter-linked mutations exhibited an Foa S phenotype in the presence of an additional copy of wild-type ADH-p53 or the wild-type reporter gene, respectively. Recessive mutations in the reporter gene were found in 87% and in the p53 gene in 9% of all mutants. Four percent of the Foa R colonies contained dominant-negative p53 mutations ( Table 2 ). Once the dominant-negative p53 mutants had been identified, the p53 plasmids were recovered and transformed into a fresh reporter strain (RBy33) to exclude artifacts of the original strain. In all cases the same dominant-negative phenotype could be reproduced. The dominant-negative mutants could be further classified by mating them to a strain with two wild-type ADH-p53 plasmids, thus characterizing the dominance of the mutant proteins in the presence of two doses of the wild-type ADH-p53 gene. The most dominant mutants were able to interfere with one and two copies of wild-type ADH-p53 (class 1). Less dominant p53 mutants could only override the activity of a single wild-type allele (class 2) (Fig. 1) . These classes represented 43% and 57% of the dominant-negative p53 mutants, respectively.
Sequences of the Dominant-Negative p53 Mutants. We then sequenced the core domains (codons 102-292) of the 49 dominant-negative mutants. Forty-one mutants had a single missense mutation and eight had an in-frame deletion. Very strikingly, the mutations clustered around five of the six known hot spot codons in the TP53 gene: 245, 248, 249, 273, and 282 (1, 2, 4). We identified five mutations in codon 245, two in codon 248, and two in codon 273. Eighty-eight percent of the missense mutations hit the five hot spot regions for mutations (132-143, 151-159, 172-179, 237-249, and 272-286) or codons for which germ-line mutations have been described (Fig. 2) (2, 5, 7, 27, 28) . Ninety-six percent of the mutations we recovered in yeast have been described in human cancers or cancer cell lines (Table 3) (4, 29, 30) . Our screen hit five of the seven amino acids important in direct DNA binding (codons 241, 248, 273, 277, and 280) and three of the four amino acids involved in zinc atom contact (codons 176, 179, and 242) (31) (32) (33) .
With the exception of H179N, all of the most dominant mutations (class 1) localized to codons 241-248 and 277-281. Eighty-three percent of the mutations in these two regions had the class 1 phenotype (Fig. 2) , indicating a strong correlation between the location of mutations and their degree of dominance.
To exclude that second mutations up-or downstream of the core domain contributed to the described phenotypes, we subcloned Nco I͞Stu I fragments (codons 159-347 encoding only the mutation of interest as confirmed by sequencing) into a wild-type ADH-p53 plasmid for the following mutants: C176R, ⌬175-180, ⌬217, G245D, R248W, R273P, P278S, and D281Y. In all cases, the same dominant-negative phenotype was reproduced (Fig. 1, Table 3 ).
Our screen hit 3 hot spot amino acids (codons 245, 248, and 273) but failed to identify mutations in the other 3 (codons 175, 249, and 282). These hot spots in human cancers are due in large part to methylation of the CpG dinucleotides present in codons 175 and 282 and exposure to aflatoxin B 1 for codon 249 (1-4, 8) ; neither situation applies to our yeast system. Two amino acid substitutions for these hot spots, R175H and R249S, were subcloned into wild-type ADH-p53 and shown to prevent UAS53ϻURA3 transcription (M.V., R.K.B., A. Fattaey, E. Harlow, and J.D.B., unpublished data). These mutants were also found to be dominant over wild type (Fig. 1, Table 3 ).
Protein Expression Levels of Dominant-Negative p53 Mutants. The wild-type and the mutant ADH-p53 genes are expressed from the same promoter in our system. To investigate whether the dominant-negative phenotypes were partially caused by an increased stability of the mutant protein, we analyzed protein levels by immunoblotting with anti-p53 antibody PAb 1801 (34) . Fig. 3 shows that protein levels for the mutant p53 proteins were similar to that of wild type.
Analysis of Recessive p53 Mutants. We also analyzed the more abundant recessive p53 mutants. Since we considered the likelihood of nonmissense mutations high, we immunoblotted protein extracts from the 67 independently obtained recessive p53 mutants. None of these clones showed full-length protein. 
DISCUSSION
Based on our work in yeast, where recessive p53 mutations outnumbered dominant ones by about two to one, we believe that recessive p53 mutations probably occur at a higher rate in human cells than dominant mutations, but that the recessive mutations are much less likely to lead to cancer (and therefore to be sequenced) because the remaining wild-type allele continues to exert its important functions. Our selection in yeast for dominant-negative TP53 mutations has identified a variety of missense mutations and in-frame deletions whose locations show a striking correlation with the hot spot regions of human cancer mutations. This suggests that the high frequency of human cancer mutations in these hot spot regions is in large part due to their dominant-negative effect on the wild-type p53 protein. Our data show that the dominantnegative mutants interfere with the wild-type protein to varying degrees; thus the amount of residual p53 activity in cells heterozygous for different p53 mutations is likely to be different. However, even for the strongest dominant-negative mutants, there is likely to be some residual p53 function. The dominant-negative interference with the function of wild-type p53 should lead to elevated rates of DNA damage, chromosome loss, and other forms of loss of heterozygosity of the TP53 locus. Loss of heterozygosity would eliminate the residual activity provided by the wild-type TP53 allele and provide the (pre-)malignant clone with further growth advantages.
Class 1 p53 mutants in our assay are more proficient than class 2 mutants in interfering with wild-type p53 function. The 
